- 优化及发展性 -
Developability assessment is not just a characterisation tool, but an enabling tool that can help companies find, develop and move the right molecules forward. It starts with designing the best screening parameters and techniques to predict the molecules’ developability and manufacturability, then coupling them with optimisation strategies to engineer and design the desired properties. If done right, it holds the promise to reduce cost and improve speed-to-market.

PEGS Europe’s 9th Annual Optimisation & Developability conference presents the proven strategies and creative approaches that scientists use to evaluate and optimize their best candidates to move forward.


Preliminary Agenda


Plenary Keynote Session

Moderator's Opening Remarks

Janine Schuurman, PhD, Corporate Vice President, Research & Innovation, Genmab BV

Bicycles and Bicycle Drug Conjugates

Sir Gregory Winter, PhD, FRS, Master, Trinity College; Co-Founder and Director, Bicycle Therapeutics

Using Protein Engineering to Make Therapeutics in Situ

Andreas G. Plückthun, PhD, Professor and Director, Department of Biochemistry, University of Zürich

DEVELOPABILITY ASSESSMENT TO GUIDE CANDIDATE SELECTION

Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increased Complexity
Philipp Amsler, MSc, Functional Lead, Downstream Processing, Novartis Pharma AG

Efficient Identification of mAb Therapeutics with Optimal Developability
Fang Yi, PhD, Principal Scientist, Biologics Discovery Sciences, Janssen Biotherapeutics, Johnson & Johnson

Molecule and Cell Line Developability Strategies to Support Fast to FTIH Studies
Mike Molloy, MSc, Director, Analytical and Characterisation, GlaxoSmithKline

MOLECULAR INSIGHTS DURING DEVELOPABILITY SCREENING

Unspecific Binding and Self Interaction during Developability
Benjamin Hackner, PhD, Scientist, Physico Chemical Analytics, Protein Sciences & CMC, MorphoSys AG

New Insights into the Mechanistics of Antibody Pharmacokinetics
Hubert Kettenberger, PhD, Senior Principal Scientist, Large Molecule Research, Roche Innovation Center Munich

OPTIMISING STRATEGIES AND TECHNOLOGIES FOR DEVELOPABILITY

Optimising Developability – Learning from Experimental Data
Lars Linden, PhD, Head, Protein Biochemistry, Biologics Research, Cell and Protein Science, Bayer AG

Rational Design of Monoclonal Antibodies with High Developability Potential
Adriana-Michelle Wolf Pérez, MSc, PhD Student, Large Protein Biophysics, Novo Nordisk

Multi-Parameter Ultra-High-Throughput Antibody Developability Screening by Mammalian Display
John McCafferty, PhD, CEO, IONTAS

RATIONAL OPTIMISATION STRATEGIES TO IMPROVE BIOLOGICS DESIGN AND FORMULATION

Using Molecular Modelling Tools to Optimize Ligand Presentation in Target Secretion Inhibitors (TSI)
Teresa Silva Barata, PhD, Senior Scientist, Product Design and Characterization, Neurology R&D, Ipsen Bioinnovation

Rational Structure Guided Approaches to Biologics Design & Optimization
Surjit Dixit, PhD, CTO, Zymeworks, Inc.

The CAMSOL Method for Rational Design of Antibody Solubility
Michele Vendruscolo, PhD, Professor, University of Cambridge

A Case Study for Developing a High Concentration Formulation for a Proof of Concept Clinical Trial
Lorène Bernasconi, PhD, Analytical Development Lab Manager, Novimmune SA

Establishing High Throughput, Low Protein Consuming Biophysical Platform for Biologics Characterization
Alexey Rak, PhD, Bio Structure and Biophysics Department, Integrated Drug Discovery, Sanofi

Sponsored Presentations

Prediction of Protein-Protein Binding Sites and Epitope Mapping
Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group


Talk Title to be Announced
Ulrich Rant, PhD, CEO, Dynamic Biosensors GmbH


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English